GlassScriptPhysician profile
Marbella Z Tran
NPI 1215129705
$10,114.55
in general payments reported to CMS, 2019-2025
56 companies · $910 in 2025
The $910 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $1,098 · 2021: $1,952 · 2022: $2,008 · 2023: $1,540 · 2024: $1,324 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.59 |
| Education | $102.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,873.60 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,129.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $769.00 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $731.37 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $526.85 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $430.93 | 2019-2024 | Rexulti |
| Astellas Pharma US INC | $393.67 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $342.40 | 2019-2025 | |
| Lundbeck LLC | $318.74 | 2020-2025 | Vyepti, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.64 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $252.37 | 2020-2025 | Airsupra, Farxiga |
| Allergan, INC. | $214.23 | 2019-2020 | |
| Daiichi Sankyo INC. | $206.81 | 2021-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $169.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.86 | 2021-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marbella Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.